HALIFAX, April 14 /CNW/ - MedMira Inc., ("MedMira") (TSXV: MIR) (NASDAQ:
MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today that the Company's Multiplo rapid test for
HIV and Hepatitis B and C will be used by the Canadian Forces Health
Services Group (CFHS). The CFHS is the designated health care provider
for Canada's military personnel, delivering medical and dental services
at military installations across Canada and overseas.
CFHS personnel can use the Multiplo rapid test in cases of occupational
exposures, medical surveillance programs, and routine medical checks.
The Multiplo test also enables healthcare professionals to quickly
screen patients and blood supply for HIV, Hepatitis B and C in the
field. Built on MedMira's patented diagnostics technology platform,
Multiplo takes less than three minutes and just a single drop of blood
to provide a simultaneous diagnosis of the three diseases.
"We are very pleased that the Canadian Forces sees the value that
Multiplo can add to the services provided by the CFHS Group to military
personnel at home and abroad. We are confident that Multiplo will
become a key tool and offer the CFHS Group flexibility and performance
in a broad range of settings from laboratories to large scale screening
programs to field hospitals in areas of conflict," said Hermes Chan,
CEO, MedMira Inc. "It is an honor and a privilege to provide our
military with a world class diagnostic technology."
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis of
infectious diseases. MedMira diagnostics are sold under the Reveal®,
MiraWell®, Multiplo™, and Miriad brands in global markets. MedMira's
rapid HIV test is the only rapid HIV test in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, including
statements regarding development of sales opportunities, which involve
risk and uncertainties and reflect the company's current expectation
regarding future events. Actual events could materially differ from
those projected herein and depend on a number of factors including, but
not limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MEDMIRA INC.
For further information:
MedMira Contact: Andrea Young